Trestle Biotherapeutics Analysis: $125K Raised
What is Trestle Biotherapeutics?
Trestle Biotherapeutics develops implantable bioengineered kidney tissue for patients with end stage renal disease. The company says its therapies aim to get patients off dialysis, delay transplantation, and eventually replace failing kidneys. The site also cites Y Combinator backing, a KidneyX prize, and a research collaboration with Humacyte.
Location
9276 Scranton Road, San Diego, California 92121, United States
Employees
1-10
Founded
2020
Revenue
<$5 Million
Product Features & Capabilities
- implantable therapeutic tissues for end-stage renal disease, bioengineered tissues to replace dialysis, potential to delay kidney transplantation, solutions for organ failure
How much Trestle Biotherapeutics raised
1 - $125K
2021Lead Investor: Y Combinator, Formic Ventures, and 1 other
Who are the founders of Trestle Biotherapeutics
BS
Ben Shepherd
Co-Founder, CEO
AC
Alice Chen
Co-Founder, Chief Scientific Officer
Competitors Overview
Trestle Biotherapeutics operates in the biotherapeutics market, focusing on bioengineered therapies for kidney disease, particularly through implantable therapeutic tissues. Its main competitors include:
-
Amgen: A leading biotechnology company known for its innovative treatments across various diseases. Amgen has a strong research and development pipeline and significant financial resources, with a revenue of $26.3 billion.
-
Gilead Sciences: Specializes in virology and oncology, with a revenue of $27.5 billion. Gilead focuses on transformative medicines and has a commitment to addressing health inequities.
-
Vertex Pharmaceuticals: Focuses on genetic disorders, particularly cystic fibrosis, with a revenue of $7.9 billion. Vertex is recognized for its innovative approaches and has a strong market presence.
-
Arcellx: Competes in the biopharma sector, offering alternative solutions in kidney disease treatment.
-
Asklepios BioPharmaceutical: Another competitor in the biopharmaceutical space, focusing on innovative therapies.
-
Zura Bio: Engages in biotechnology, providing competition in the therapeutic landscape.
-
Tobira, Glycominds, My Reason, and Liberty Biotech: These companies also focus on biotherapeutics, particularly in kidney disease, but may not specialize in bioengineered organ solutions like Trestle.
Trestle Biotherapeutics distinguishes itself by utilizing stem cell biology and 3D biofabrication technology to potentially restore renal function, which may provide a unique advantage over competitors that do not specialize in bioengineered organ solutions.
Business Model
Focus on partnerships, grants, and funding for research and development revenue.
Market Focus
Trestle Biotherapeutics primarily focuses on the biopharmaceutical industry, specifically developing bioengineered therapies for kidney disease, including implantable therapeutic tissues for patients with end-stage renal disease (ESRD).
Investors
- KidneyX Innovation Accelerator
- Acequia Capital (AceCap)
- Y Combinator
- Formic Ventures
- Black Mountain Ventures
- C3 Ventures
- Axial VC
- Wellcome Leap HOPE Program
See something that needs updating? Suggest edits to this profile.